The finding of a strong inverse correlation between MYB and MAFB in MLL-driven leukaemia suggests that MAFB could serve as a new useful prognostic biomarker or predictive toward future MYB-targeted therapeutic strategies. This evidence concerns the gene KMT2A and leukemia.